CANNABIDIORCOL (CBD-C1)

WHAT IS CANABIDIORCOL (CBD-C1)?

Cannabidiorcol (CBD-C1) is a type of Cannabidiol (CBD) along other types namely Cannabidiol – C1 (CBD-C1), Cannabidiol – C4 (CBD-C4)  and Cannabidiolic Acid (CBDA). Cannabidiorcol (CBD-C1) is also known as Cannabidiorocol – O 1821 – Cannabidiorcol. Its Chemical formula is written as C17H22O2, having a molecular weight of 258 and LogP of 4.4 with the density being 1.073g/cm3. Its boiling point is 401.6C at 760 mmHg. There exist two types of Cannabidiol (CBD) namely the natural Cannabidiol (CBD) and the synthetic Cannabidiol (CBD). The natural Cannabidiol (CBD) is derived from plants while the synthetic Cannabidiol (CBD) is arrived at in the laboratory through the process of synthesiation.

Of the over 120 natural cannabinoids identified in Cannabis plant, seven have been classified as CBD-type compounds including CBD. All of them have the same absolute configuration than CBD; they are 5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-dioles retaining the trans-(1 R,6 R) configuration. Cannabidiolic acid (CBDA) and cannabidivarinic acid (CBDVA-C3) are C3′-carboxylic derivatives, whereas cannabidiorcol (CBD-C1), cannabidiol-C4 also named as nor -cannabidiol (CBD-C4), and cannabidivarin (CBDV) differ from CBD by the length of their C4′-side chain. Cannabidiol monomethyl ether (CBDM), the C6′-methoxy CBD analog, was also isolated from the plant. Despite the potential therapeutic interest of these naturally occurring CBD derivatives, only a few related pharmacological studies have been reported.

The first discovery of an individual cannabinoid was made, when British chemist, Robert S. Cahn reported the partial structure of Cannabinol (CBN), which he later identified as fully formed in 1940. Two years later, American chemist, Roger Adams, made history when he successfully isolated the first cannabinoid, Cannabidiol (CBD). His research is also responsible for the discovery of Tetrahydrocannabinol (THC).

Cannabidiorcol (CBD-C1) as one of the naturally occurring derivatives of Cannabidiol (CBD) has many potential therapeutic interest but despite the interest, there exist only a fragment of pharmacological studies on it. Nonetheless, that much has not been reported concerning it does not mean it won’t gain attention in the future.

HOW IT WORKS

Members of the CBD class of cannabinoids bind weakly to CB1 receptors and act as an “inverse agonist” at the CB2 receptors (Ligresti, et al, 2016). A molecule that can combines with a receptor on a cell to produce a physiological reaction is referred to as an agonist. An inverse agonist, then, is an agent that aids the combination with the receptor to bring about a counter response to what would have occurred naturally. This explains part of the impact of CBD in the human body system. One of such impact is the moderation of THC.

THERAPEUTIC BENEFITS

Generally, Cannabidiols (CBDs) act as anti-depressant, anti-anxiety, anti-inflammatory and antipsychotic agent and this can be said to be true for Cannabidiorcol (CBD-C1) since it belongs to the family too. However, beyond the list, Cannabidiorcol (CBD-C4) is capable of acting as an anti-cancer, anti-nausea and antioxidant agent.

INTERESTING FACTS

Cannabidiorcol (CBD-C1) as a member of Cannabidiol (CBD) does not have intoxicating and psychoactive abilities and can be used for neurodevelopmental diseases.

REFERENCES

Aizpurua-Olaizola O., Soydaner U., Öztürk E., Schibano D., Simsir Y., Navarro P., et al. (2016). Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J. Nat. Prod. 79 324–331. 10.1021/acs.jnatprod.5b0094.

ElSohly M. A., Gul W. (2014). “Constituents of cannabis sativa,” in Handbook of Cannabis , ed. Pertwee R. G. (Oxford: Oxford University Press; ), 3–22. 10.1093/acprof [CrossRef] [Google Scholar]

ElSohly M. A., Slade D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78 539–548. 10.1016/j.lfs.2005.09.011 [ PubMed] [ CrossRef] [ Google Scholar ]

Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiological reviews. 2016 Oct;96(4):1593-659.

Leave a Comment

Your email address will not be published. Required fields are marked *